Learn about Jivi
What is Jivi?
Jivi is used in previously treated adults and adolescents 12 years of age or older with hemophilia A for:1
- Routine prophylactic treatment to prevent or reduce the frequency of
bleeding episodes - Control and prevention of episodic bleeding
- Peri-operative management of bleeding (surgical prophylaxis)
Jivi does not contain von Willebrand factor and is not indicated for the treatment of von Willebrand disease.
Safety and efficacy for previously untreated patients (PUPs) have not been studied.
Jivi’s mechanism of action*
Jivi is a PEGylated form of recombinant antihemophilic factor.
Jivi temporarily replaces the missing endogenous Factor VIII needed
for effective prevention and control of bleeding episodes in patients
with congenital hemophilia A.1
PEG=polyethylene glycol.
* Clinical significance has not been established.
